Does testosterone influence the association between sleep and frailty in men: results from the European Male Aging Study.

Aged Humans Male Frailty / diagnosis Frail Elderly Testosterone Aging Sleep
Ageing EMAS study Frailty Sleep Testosterone

Journal

BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548

Informations de publication

Date de publication:
06 Dec 2023
Historique:
received: 29 12 2022
accepted: 01 11 2023
medline: 11 12 2023
pubmed: 7 12 2023
entrez: 6 12 2023
Statut: epublish

Résumé

Previous studies have suggested an association between sleep disturbance and frailty. The mechanism is unknown, although it has been suggested that hormonal factors may play a role. The aim was to determine the association between sleep duration, sleep quality and frailty, and to determine whether testosterone influenced this association. Males aged 40-79 years were recruited from eight European centres to the European Male Aging Study (EMAS). Subjects completed an interviewer-assisted questionnaire including questions regarding sleep quality and duration. Sleep quality was scored 0-20 and categorised as 0-4, 5-9, 10-14, and 15-20, with higher scores indicating poorer quality. A 39-component frailty index (FI) was constructed. Total testosterone levels were measured. The association between sleep duration, sleep quality and the FI was assessed using negative binomial regression, with adjustment for putative confounders including testosterone level. Two thousand three hundred ninety-three participants contributed data to the analysis. The mean age was 63.3 years and mean sleep duration was 7.01 h. The mean frailty index was 0.15. Mean testosterone levels declined with decreasing sleep quality. After adjustment, compared to those with a sleep score of 0-4, the FI was 57% (95% CI 38%, 78%) higher among those with a sleep score of 15-20. After adjustment compared to those with normal sleep duration (6-9 h), those with a short (< 6 h) and long (≥ 9 h) sleep duration had a 16% (95% CI 6%, 28%) and 11% (95% CI 0%, 23%) higher FI, respectively. Adjustment for testosterone did not influence the strength of either association. Frailty is associated with impaired sleep quality and sleep duration. The association cannot, however, be explained by variation in testosterone levels.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies have suggested an association between sleep disturbance and frailty. The mechanism is unknown, although it has been suggested that hormonal factors may play a role.
METHODS METHODS
The aim was to determine the association between sleep duration, sleep quality and frailty, and to determine whether testosterone influenced this association. Males aged 40-79 years were recruited from eight European centres to the European Male Aging Study (EMAS). Subjects completed an interviewer-assisted questionnaire including questions regarding sleep quality and duration. Sleep quality was scored 0-20 and categorised as 0-4, 5-9, 10-14, and 15-20, with higher scores indicating poorer quality. A 39-component frailty index (FI) was constructed. Total testosterone levels were measured. The association between sleep duration, sleep quality and the FI was assessed using negative binomial regression, with adjustment for putative confounders including testosterone level.
RESULTS RESULTS
Two thousand three hundred ninety-three participants contributed data to the analysis. The mean age was 63.3 years and mean sleep duration was 7.01 h. The mean frailty index was 0.15. Mean testosterone levels declined with decreasing sleep quality. After adjustment, compared to those with a sleep score of 0-4, the FI was 57% (95% CI 38%, 78%) higher among those with a sleep score of 15-20. After adjustment compared to those with normal sleep duration (6-9 h), those with a short (< 6 h) and long (≥ 9 h) sleep duration had a 16% (95% CI 6%, 28%) and 11% (95% CI 0%, 23%) higher FI, respectively. Adjustment for testosterone did not influence the strength of either association.
CONCLUSION CONCLUSIONS
Frailty is associated with impaired sleep quality and sleep duration. The association cannot, however, be explained by variation in testosterone levels.

Identifiants

DOI: 10.1186/s12877-023-04450-8 PMID: 38057724 PMC: PMC10702097
pubmed: 38057724
doi: 10.1186/s12877-023-04450-8
pii: 10.1186/s12877-023-04450-8
pmc: PMC10702097
doi:

Substances chimiques

Testosterone 3XMK78S47O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

813

Subventions

Organisme : Commission of the European Communities Fifth Framework Program 'Quality of Life and Management of Living Resources'
ID : QLK6-CT-2001-00258

Informations de copyright

© 2023. The Author(s).

Références

N Engl J Med. 2010 Jul 8;363(2):123-35
pubmed: 20554979
J Clin Epidemiol. 1993 Feb;46(2):153-62
pubmed: 8437031
Int J Environ Res Public Health. 2020 Dec 17;17(24):
pubmed: 33348703
J Am Geriatr Soc. 2009 Nov;57(11):2094-100
pubmed: 19793356
Lancet. 2019 Oct 12;394(10206):1365-1375
pubmed: 31609228
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Rev Bras Enferm. 2016 Jun;69(3):435-42
pubmed: 27355291
J Nutr Health Aging. 2019;23(1):63-67
pubmed: 30569070
Eur Geriatr Med. 2022 Jun;13(3):663-673
pubmed: 35107811
Geriatr Gerontol Int. 2014 Jul;14(3):605-12
pubmed: 24020502
Sleep Breath. 2020 Sep;24(3):1187-1197
pubmed: 32215833
Int J Androl. 2009 Feb;32(1):11-24
pubmed: 18328041
Aust N Z J Psychiatry. 1976 Mar;10(1):27-32
pubmed: 1065311
Br J Urol. 1995 May;75(5):622-30
pubmed: 7542132
J Nutr Health Aging. 2018;22(9):1066-1071
pubmed: 30379304
J Steroid Biochem Mol Biol. 2006 Jun;99(4-5):182-8
pubmed: 16621522
BMC Geriatr. 2020 Jan 6;20(1):9
pubmed: 31906855
Int J Impot Res. 2022 Dec 6;:
pubmed: 36473958
Geriatr Gerontol Int. 2017 Dec;17(12):2573-2578
pubmed: 28656599
Am J Med. 1986 Mar;80(3):429-34
pubmed: 3953620
J Am Geriatr Soc. 2009 Nov;57(11):2085-93
pubmed: 19793160
Sleep Med. 2012 Dec;13(10):1217-25
pubmed: 22705247
Int J Environ Res Public Health. 2020 Jul 20;17(14):
pubmed: 32698531
J Clin Endocrinol Metab. 2008 Jul;93(7):2602-9
pubmed: 18413429
Geriatr Gerontol Int. 2017 Oct;17(10):1481-1487
pubmed: 27679974
J Am Geriatr Soc. 2014 Apr;62(4):721-6
pubmed: 24635726
Am J Epidemiol. 2009 Jul 15;170(2):193-202
pubmed: 19465743
J Am Geriatr Soc. 1990 Oct;38(10):1105-12
pubmed: 2229864
J Am Med Dir Assoc. 2016 Mar 1;17(3):269-71
pubmed: 26832127
J Clin Endocrinol Metab. 2018 Feb 1;103(2):701-709
pubmed: 29186457
PLoS One. 2019 Oct 17;14(10):e0224122
pubmed: 31622445
J Clin Epidemiol. 1988;41(4):313-21
pubmed: 3351539
BMC Geriatr. 2008 Sep 30;8:24
pubmed: 18826625
Ann Rheum Dis. 2009 May;68(5):690-5
pubmed: 18653627
Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Oct 10;40(10):1252-1256
pubmed: 31658526
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012
Compr Psychoneuroendocrinol. 2022 Sep 09;12:100158
pubmed: 36148025
J Am Geriatr Soc. 2008 May;56(5):898-903
pubmed: 18363679
J Nutr Health Aging. 2022;26(4):383-390
pubmed: 35450995
J Aging Health. 2020 Jan-Feb;32(1):42-51
pubmed: 30270714
World J Urol. 2019 Jul;37(7):1449-1453
pubmed: 30225799
J Am Med Dir Assoc. 2015 Jul 1;16(7):630.e1-6
pubmed: 25959075

Auteurs

Seema D Sharma (SD)

Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology Medicine and Health, University of Manchester, The Stopford Building, Oxford Road, Manchester, M13 9PT, UK. s.d.sharma@doctors.org.uk.

Michael J Cook (MJ)

Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology Medicine and Health, University of Manchester, The Stopford Building, Oxford Road, Manchester, M13 9PT, UK.

Leen Antonio (L)

Department of Clinical and Experimental Medicine, KU Leuven, Laboratory of Clinical and Experimental Endocrinology, Louvain, Belgium.
Department of Endocrinology, University Hospitals Leuven, Louvain, Belgium.

Evelien Gielen (E)

Centre for Metabolic Bone Diseases, Department of Geriatrics, University Hospitals Leuven, Louvain, Belgium.

Gyorgy Bartfai (G)

Department of Obstetrics, Gynaecology and Andrology, Albert Szent-Gyorgy Medical University, Szeged, Hungary.

Felipe F Casanueva (FF)

Department of Medicine, CIBER de Fisiopatología Obesidad y Nutricion, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago (CHUS), Instituto Salud Carlos III, CB06/03, Santiago de Compostela, Spain.

Ilpo T Huhtaniemi (IT)

Institute of Reproductive and Developmental, Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Campus, London, UK.

Mario Maggi (M)

Andrology Unit, Mario Serio Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Margus Punab (M)

Andrology Clinic, Tartu University Hospital, Tartu, Estonia.
Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Giulia Rastrelli (G)

Andrology Unit, Mario Serio Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Jolanta Slowikowska-Hilczer (J)

Department of Andrology and Reproductive Endocrinology, Medical University of Łódź, Łódź, Poland.

Jos Tournoy (J)

Department of Geriatrics, University Hospitals Leuven, Louvain, Belgium.
Department of Public Health and Primary Care, KU Leuven, Louvain, Belgium.

Dirk Vanderschueren (D)

Department of Clinical and Experimental Medicine, KU Leuven, Laboratory of Clinical and Experimental Endocrinology, Louvain, Belgium.
Department of Endocrinology, University Hospitals Leuven, Louvain, Belgium.

Frederick C Wu (FC)

Department of Endocrinology, Manchester University NHS Foundation Trust, Manchester, UK.

Terence W O'Neill (TW)

Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology Medicine and Health, University of Manchester, The Stopford Building, Oxford Road, Manchester, M13 9PT, UK.
NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Does testosterone influence the association...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Does testosterone influence the association...
Recherchemedicale.com › États, signes et symptômes pathologiques › Processus pathologiques › Fragilité › Does testosterone influence the association...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Personne âgée fragile › Does testosterone influence the association...
Recherchemedicale.com › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de la testostérone › Testostérone › Does testosterone influence the association...
Recherchemedicale.com › Phénomènes physiologiques › Croissance et développement › Vieillissement › Does testosterone influence the association...
Recherchemedicale.com › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Sommeil › Does testosterone influence the association...